S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

LUNGevity Foundation Appoints Sam Rogers as Chief Development Officer

With nearly two decades of experience in cancer philanthropy, Sam Rogers has joined the LUNGevity Foundation as Chief Development Officer. His appointment aims to bolster the organization's fundraising capacity, ensuring that critical research and patient advocacy initiatives receive the sustained investment necessary to improve lung cancer outcomes.

LUNGevity Foundation Appoints Sam Rogers as Chief Development Officer
Photo: Bio & News

Rogers arrives at the Bethesda-based foundation following a four-year tenure at the American Association for Cancer Research (AACR) Foundation, where he directed philanthropic strategy. His background also includes over eight years of leadership at the Lymphoma Research Foundation, covering diverse fundraising channels and patient communications. At LUNGevity, he will oversee a comprehensive strategy to expand donor and partner relationships across the entire lung cancer continuum.

Andrea Ferris, president and CEO of LUNGevity, noted that the move is intended to translate emerging scientific opportunities into tangible progress for patients. As the organization scales its focus on early detection and precision medicine, the role will prioritize creating new pathways for philanthropic support. Rogers, who holds degrees from The New School, enters the organization as it continues its mission to address the needs of patients from initial diagnosis through survivorship.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!